Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.

Lane JW, Rehak NN, Hortin GL, Zaoutis T, Krause PR, Walsh TJ.

Clin Chim Acta. 2008 Jan;387(1-2):145-9. Epub 2007 Aug 30.

2.

The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.

Rust DM, Jameson G.

Oncol Nurs Forum. 1998 Jan-Feb;25(1):35-48. Review.

PMID:
9460772
3.

Liposomal and lipid-based formulations of amphotericin B.

de Marie S.

Leukemia. 1996 Jun;10 Suppl 2:s93-6. Review.

PMID:
8649062
4.

Amphotericin B formulations: a comparative review of efficacy and toxicity.

Hamill RJ.

Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4. Review.

PMID:
23729001
5.

Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.

Loo AS, Muhsin SA, Walsh TJ.

Expert Opin Drug Saf. 2013 Nov;12(6):881-95. doi: 10.1517/14740338.2013.827168. Epub 2013 Aug 10. Review.

PMID:
23931455
6.

Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.

Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II.

Medicine (Baltimore). 2010 Jul;89(4):236-44. doi: 10.1097/MD.0b013e3181e9441b. Review.

7.

Development of liposomal amphotericin B formulation.

Gulati M, Bajad S, Singh S, Ferdous AJ, Singh M.

J Microencapsul. 1998 Mar-Apr;15(2):137-51. Review.

PMID:
9532520
8.

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Tiphine M, Letscher-Bru V, Herbrecht R.

Transpl Infect Dis. 1999 Dec;1(4):273-83. Review.

PMID:
11428998

Supplemental Content

Support Center